None
Quote | Tissue Regenix Group PLC (OTCMKTS:TSSNF)
Last: | $0.005 |
---|---|
Change Percent: | 0.0% |
Open: | $0.005 |
Close: | $0.005 |
High: | $0.005 |
Low: | $0.005 |
Volume: | 31,275 |
Last Trade Date Time: | 12/20/2021 04:54:47 pm |
News | Tissue Regenix Group PLC (OTCMKTS:TSSNF)
(NewsDirect) Tissue Regenix Group PLC (AIM:TRX) CEO Danny Lee and CFO David Cocke discussed the company's 2023 operational and financial performance in an interview with Proactive's Stephen Gunnion. Tissue Regenix is a global leader in regenerative medicine, focusing on tissue-based s...
(NewsDirect) Tissue Regenix Group PLC (AIM:TRX) chief executive Danny Lee and chief financial officer David Cocke speak to Thomas Warner from Proactive London after the regenerative medicine company released its interim results for the first six months of 2023. Cocke reports that the comp...
Message Board Posts | Tissue Regenix Group PLC (OTCMKTS:TSSNF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Tissue Regenix Group PLC Company Name:
TSSNF Stock Symbol:
OTCMKTS Market:
Tissue Regenix Group PLC Website:
(NewsDirect) Tissue Regenix Group PLC (AIM:TRX) CEO Danny Lee and CFO David Cocke discussed the company's 2023 operational and financial performance in an interview with Proactive's Stephen Gunnion. Tissue Regenix is a global leader in regenerative medicine, focusing on tissue-based s...
(NewsDirect) Tissue Regenix Group PLC (AIM:TRX) chief executive Danny Lee and chief financial officer David Cocke speak to Thomas Warner from Proactive London after the regenerative medicine company released its interim results for the first six months of 2023. Cocke reports that the comp...
(NewsDirect) Tissue Regenix Group PLC (AIM:TRX, OTC:TSSNF) chief executive Danny Lee and chief financial officer David Cocke visit Proactive's London studio to speak with Thomas Warner after releasing final results for 2022. They explain why they believe 2022 was a "transformational" ...